A second drug has been approved in the US for myelofibrosis, a rare bone marrow disorder that disrupts the body’s normal production of blood cells. The drug, Inrebic (fedratinib), has been authorised for primary myelofibrosis as well as secondary post-polycythemia vera or post-essential thrombocythemia disease.
